A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. - Wikidata - awgldk - TriplyDB

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.

http://www.wikidata.org/entity/Q30210342

about

Emerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?Delivering vaccines to the people who need them most Tackling a novel lethal virus: a focus on H7N9 vaccine development.Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.Considerations for the rapid deployment of vaccines against H7N9 influenza.Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.Emerging influenza viruses and the prospect of a universal influenza virus vaccine.Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.A paradigm shift in vaccine production for pandemic influenza.Refining the approach to vaccines against influenza A viruses with pandemic potential.Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9).H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial.H7N9 influenza virus neutralizing antibodies that possess few somatic mutations A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.An overview of the regulation of influenza vaccines in the United States.Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses.A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines.Humoral and Cellular Immunogenicity Induced by Avian Influenza A (H7N9) DNA Vaccine in Mice Evaluation of MDCK cell-derived influenza H7N9 vaccine candidates in ferrets A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model.Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.A live attenuated vaccine prevents replication and transmission of H7N9 virus in mammals.Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes.Antigenic characterization of influenza viruses produced using synthetic DNA and novel backbones.Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge.Antibody Immunity Induced by H7N9 Avian Influenza Vaccines: Evaluation Criteria, Affecting Factors, and Implications for Rational Vaccine Design.An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.From empiricism to rational design: a personal perspective of the evolution of vaccine development.A live attenuated vaccine prevents replication and transmission of H7N9 highly pathogenic influenza viruses in mammals CD4 T cells in protection from influenza virus: Viral antigen specificity and functional potential

P2860

Q26783481-13AA550F-0107-4810-A027-D714A3EA436F Q28082744-192CC34D-DCEE-4E99-A3DF-052662A61164 Q30148631-95A42E33-711F-430E-A9ED-5FBC64FF1422 Q30151798-F973BAD6-58FC-434A-B2A4-D6A37B171B32 Q30201991-7D90D434-CD13-4066-815B-12225A692482 Q30204573-DAEA77C0-14C2-4897-9EA1-C7C702560BE5 Q30364635-44943422-0F07-4C38-827C-61628809572F Q30372141-6686E924-9B8A-4B01-85F6-817A3AADC297 Q30372274-D6310E2F-F0F8-43EF-8659-D17D0771C62E Q30372696-9008D28A-5F49-4080-8D0E-D17508A5EE81 Q30377766-E870E61C-2BDE-40B0-A9B2-75796633C282 Q30381595-440B571A-2C68-4000-A1FD-00089585BD03 Q30382351-6F848A90-3B0E-4908-9077-CE5535890DDF Q30382548-49FB3DE0-EDDE-4448-988F-94014134DB85 Q30385356-7560184D-0632-456F-BA41-918A18B0CB97 Q30385570-7FA0D67A-51DB-44D2-8BE2-77A9447305B2 Q30390639-DC2783D8-B2D8-45AD-92B1-EFDC2E49C636 Q30392895-2DDADF27-7392-466C-82CD-400232D94885 Q30401521-30EEE81C-C2B3-4180-8863-02E9400CF0CA Q33683108-D1FD4FBA-AED9-4606-A7FA-508FE7446189 Q33880398-F462DF44-9B6C-450E-86FB-865CACAD06AA Q35208516-083C2CE7-8E9E-48F1-A69F-12A999636CAA Q35474243-DAFD23E1-4E8C-465B-9BEF-087AD8C93850 Q35550576-3E5A8477-AA5E-4093-A441-BC003DE583FE Q35710438-3C93DF2E-C3C5-49DF-BDED-32C277F8C004 Q35919479-4C255CF5-04D2-48F1-A4AB-A6292890DBE4 Q35990859-1360B437-E218-4E33-A309-A24EEC1B1707 Q36078779-A3457229-9A51-4DA7-8282-44C98FF8269E Q36316782-AD90E7FD-466F-471E-8EA1-3156443C1DD2 Q37083396-67DCF57F-799D-4563-9109-BDD096E72F5D Q40116170-A7BF96CC-3606-443B-99D2-FD5EACD5CEC4 Q41919615-7D5551FD-A8AC-44A7-AFAF-C22D970EC473 Q47105782-A5A2C1D7-6C6B-48A3-B151-F9808138CE7E Q47633699-3EE4CB75-C682-4448-A22B-98CDD9EA4D6A Q56971807-BFA15A9E-5807-4A02-BB88-FFF61FFC299E Q57094380-D15A0461-FDFC-4B7D-BC89-F7FCA3E4E0E0

P2860

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.

http://www.wikidata.org/entity/Q30210342

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.

@ast

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.

@en

type

label

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.

@ast

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.

@en

prefLabel

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.

@ast

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.

@en

P1433

Q30210342-045D15B4-6BEC-4758-A0C6-9B38376DA912

P1476

Q30210342-A0D819BB-B0AE-422D-8BA2-2B88938361C2

P2093

Q30210342-06EC58DE-8E95-4E26-B4D1-E9D31B13D60D

Q30210342-5B6ADCF6-E663-4765-AC4E-EA623D138B38

Q30210342-60F024B1-BB59-453C-91EA-90D074F4145A

Q30210342-C3ACC659-DE27-467B-B661-A074DBE6DECA

Q30210342-DBB039F1-E46C-4484-91BE-0111F1C61C5A

Q30210342-FC609708-33BC-46F6-832F-A6F5F8742507

P2860

Q30210342-0B445842-01B0-498E-8A7D-C25BC82DAB5A

Q30210342-0D9A169E-CAA4-4AC9-AE84-E39C5247EC20

Q30210342-11F7F209-AB79-4237-A3B6-5EC910EC38A9

Q30210342-190B4534-536A-4E33-B3AD-95DB53807763

Q30210342-1A81DE21-B5AD-4FE7-B617-F0865A687FAC

Q30210342-1DF691BC-5B7B-478C-86CF-B15D5E6D8E45

Q30210342-204E9B3E-74C6-4317-BBD8-64405079E18C

Q30210342-216171E0-201D-4519-8713-BB7A6955FBC3

Q30210342-280988B9-0A30-40C8-A9E5-909C5AE83A29

Q30210342-290AAC65-4612-4A0B-9834-DB8E037D3F92

P304

Q30210342-D9FC5110-D3FD-4ADC-9AF0-D0E302E76B65

P31

Q30210342-2B89290A-E1C9-4A0E-8CBA-B0D25136CEA0

P356

Q30210342-EF911E30-B19C-43E0-9A06-4F911A4AE32F

P407

Q30210342-24A498BF-6AF2-44B1-8169-E1256BA34860

P433

Q30210342-4F43A484-2AD9-4D58-87EA-9F7EC8F0AB61

P478

Q30210342-37782D71-0AD3-487C-9936-F8C55A2EC8EC

P577

Q30210342-ADD47022-0FC9-479D-8605-03300C14E6BC

P5875

Q30210342-75F638B3-1151-412A-A646-B7D80789ABE1

P698

Q30210342-5C4CDE18-5BA5-4296-B76C-4D9E2365D6C7

P921

Q30210342-E26EECD4-F161-49DB-883A-5BE2590B6978

P356

SCITRANSLMED.3008761

P1433

Science Translational Medicine

P1476

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.

@en

P2093

Giovanni Della Cioppa

http://www.w3.org/2001/XMLSchema#string

Matthew Hohenboken

http://www.w3.org/2001/XMLSchema#string

Niranjan Kanesa-Thasan

http://www.w3.org/2001/XMLSchema#string

Philip R Dormitzer

http://www.w3.org/2001/XMLSchema#string

Stephan A Bart

http://www.w3.org/2001/XMLSchema#string

Vas Narasimhan

http://www.w3.org/2001/XMLSchema#string

P2860

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

Human infection with a novel avian-origin influenza A (H7N9) virus

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

H7N9 influenza viruses are transmissible in ferrets by respiratory droplet.

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

P304

234ra55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3008761

http://www.w3.org/2001/XMLSchema#string

P407

P433

234

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262017978

http://www.w3.org/2001/XMLSchema#string

P698

24786323

http://www.w3.org/2001/XMLSchema#string

P921